Case–Control Study on TNFRSF6B Gene Polymorphism and Susceptibility to Gastric Cancer in a Chinese Han Population

References

• Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (London, England). 2020;396(10251):635–648. doi:10.1016/S0140-6736(20)31288-5
   PubMed Web of Science ®Google Scholar
• Wang F, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun. 2019;39(1):10. doi:10.1186/s40880-019-0349-9
   PubMed Web of Science ®Google Scholar
• Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39(7):1010428317714626. doi:10.1177/101042831771462628671042
   PubMedGoogle Scholar
• Tan H, Zhang S, Zhang J, et al. Long non-coding RNAs in gastric cancer: new emerging biological functions and therapeutic implications. Theranostics. 2020;10(19):8880–8902. doi:10.7150/thno.4754832754285
   PubMed Web of Science ®Google Scholar
• Li-Sheng Chen S, Ching-Yuan Fann J, Sipeky C, et al. Risk prediction of prostate cancer with single nucleotide polymorphisms and prostate specific antigen. J Urol. 2019;201(3):486–495. doi:10.1016/j.juro.2018.10.01530366021
   PubMed Web of Science ®Google Scholar
• Mueller AM, Pedré X, Killian S, David M, Steinbrecher A. The decoy receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol. 2009;209(1–2):57–64. doi:10.1016/j.jneuroim.2009.01.02419269042
   PubMed Web of Science ®Google Scholar
• Chen G, Rong M, Luo D. TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol Res Pract. 2010;206(9):631–641. doi:10.1016/j.prp.2010.05.01120591579
   PubMed Web of Science ®Google Scholar
• Yu W, Xu Y, Tao Y, et al. DcR3 regulates the growth and metastatic potential of SW480 colon cancer cells. Oncol Rep. 2013;30(6):2741–2748. doi:10.3892/or.2013.276924101127
   PubMed Web of Science ®Google Scholar
• Zhao T, Xu Y, Ren S, et al. The siRNA silencing of DcR3 expression induces Fas ligand-mediated apoptosis in HepG2 cells. Exp Ther Med. 2018;15(5):4370–4378.29725377
   PubMed Web of Science ®Google Scholar
• Ren Z, Zhu J, Gu H, et al. Decoy receptor 3 polymorphisms are not associated with the risk of esophageal cancer in a Chinese population. Biomarkers. 2014;19(4):340–344. doi:10.3109/1354750X.2014.91534324786982
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luo J, He R, et al. Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases. Oncotargets Ther. 2016;9:4959–4968. doi:10.2147/OTT.S105225
   Web of Science ®Google Scholar
• Zhang Y, Huang S, Leng Y, et al. Effect of DcR3-specific siRNA on cell growth suppression and apoptosis induction in glioma cells via affecting ERK and AKT. Oncotargets Ther. 2016;9:5195–5202. doi:10.2147/OTT.S108395
   Web of Science ®Google Scholar
• Zhang X, Takata K, Cui W, et al. Protocadherin γ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth. Mol Med Rep. 2016;14(5):4622–4628. doi:10.3892/mmr.2016.580827748813
   PubMed Web of Science ®Google Scholar
• Wei Y, Chen X, Yang J, et al. DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. Am J Cancer Res. 2019;9(12):2618–2633.31911850
   PubMed Web of Science ®Google Scholar
• Macher-Goeppinger S, Aulmann S, Wagener N, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia (New York, N Y). 2008;10(10):1049–1056. doi:10.1593/neo.08626
   Web of Science ®Google Scholar
• Bou-Dargham MJ, Liu Y, Sang QA, Zhang J, Seagroves T. Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3. PLoS One. 2018;13(12):e0207799. doi:10.1371/journal.pone.020779930513096
   PubMed Web of Science ®Google Scholar
• Ruan Y, Huang S, He D, et al. Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells. Neoplasma. 2015;62(4):574–581. doi:10.4149/neo_2015_06925997959
   PubMed Web of Science ®Google Scholar
• Xiong G, Guo H, Wang K, et al. Polymorphisms of decoy receptor 3 are associated with risk of esophageal squamous cell carcinoma in Chinese Han. Tumour Biol. 2010;31(5):443–449. doi:10.1007/s13277-010-0053-520567955
   PubMedGoogle Scholar
• Dai L, Fu L, Liang Y, et al. A functional polymorphism rs2257440 in the gene DcR3 regulates its expression via MTF-1 in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2017;10(11):11006–11013.31966445
   PubMed Web of Science ®Google Scholar
• Fu Z, Chen S, Liu S, et al. DcR3 gene polymorphisms are associated with sporadic breast infiltrating ductal carcinoma in Northeast Chinese women. Oncotarget. 2016;7(36):57970–57977. doi:10.18632/oncotarget.1115327517320
   PubMedGoogle Scholar
• Shi G, Wu Y, Zhang J, Wu J. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol (Baltimore, Md: 1950). 2003;171(7):3407–3414. doi:10.4049/jimmunol.171.7.3407
   PubMed Web of Science ®Google Scholar
• Chang Y, Chan Y, Jackson DG, Hsieh S. The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion. J Immunol (Baltimore, Md: 1950). 2006;176(1):173–180. doi:10.4049/jimmunol.176.1.173
   Web of Science ®Google Scholar
• Edfeldt K, Daskalakis K, Bäcklin C, et al. DcR3, TFF3, and midkine are novel serum biomarkers in small intestinal neuroendocrine tumors. Neuroendocrinology. 2017;105(2):170–181. doi:10.1159/00045289127829249
   PubMed Web of Science ®Google Scholar
• Hu R, Liu W, Qiu X, et al. Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR3 and ERK1/2. Oncol Lett. 2016;11(3):1835–1840. doi:10.3892/ol.2016.413326998086
   PubMed Web of Science ®Google Scholar